Pre-activation of mesenchymal stem cells with TNF-α, IL-1β 2 and nitric oxide enhances its paracrine effects on radiation-induced intestinal injury

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chen, Hao ^a,b   Min, Xiao Hui ^a   Wang, Qi Yi ^b   Leung, Felix W ^c   Shi, Liu ^d   Zhou, Yu ^e   Yu, Tao ^a   Wang, Chuan Ming ^f   An, Geng ^g   Sha, Wei Hong ^b   Chen, Qi Kui ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Ganzhou City People's Hospital   (China)

^e GUANGDONG MEDICAL UNIVERSITY   (China)

^f Shenzhen Nanshan People s Hospital and the 6th Affiliated Hospital of Shenzhen University Medical School   (China)

^g GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CULTURE MEDIUM; HEME OXYGENASE 1; INTERLEUKIN 1BETA; NITRIC OXIDE; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; APOPTOSIS; CELL PROLIFERATION; CULTURE MEDIUM; DRUG EFFECTS; INFLAMMATION; INTESTINAL DISEASES; INTESTINE MUCOSA; MESENCHYMAL STROMA CELL; METABOLISM; MORTALITY; PARACRINE SIGNALING; PATHOLOGY; PHARMACOLOGY; RADIATION DOSE; RADIATION INJURIES, EXPERIMENTAL; RADIATION RESPONSE; RAT; REGENERATION; STEM CELL;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; HEME OXYGENASE-1; INFLAMMATION; INFLAMMATION MEDIATORS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-1BETA; INTESTINAL DISEASES; INTESTINAL MUCOSA; MESENCHYMAL STROMAL CELLS; NITRIC OXIDE; PARACRINE COMMUNICATION; RADIATION DOSAGE; RADIATION INJURIES, EXPERIMENTAL; RATS; REGENERATION; STEM CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924706315     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08718     Document Type: Article

References (55)

1. Potten, C. S. Radiation, the ideal cytotoxic agent for studying the cell biology of tissues such as the small intestine. Radiat. Res. 161, 123-136 (2004).
2. Umar, S. Intestinal stem cells. Curr. Gastroenterol. Rep. 12, 340-348 (2010).
3. Shadad, A. K. et al. Gastrointestinal radiation injury: Prevention and treatment. World J. Gastroenterol 19, 199-208 (2013).
4. Keating, A. Mesenchymal stromal cells: new directions. Cell Stem Cell 10, 709-716 (2012).
5. Menasché, P. Stem cells for clinical use in cardiovascular medicine: current limitations and future perspectives. Thromb. Haemost 94, 697-701 (2005).
6. Marx, J. Cancer research. Mutant stem cells may seed cancer. Science 301, 1308-1310 (2003).
7. Sell, S. On the stem cell origin of cancer. Am. J. Pathol. 176, 2584-2494 (2010).
8. Hung, S. C. et al. Angiogenic Effects of Human Multipotent Stromal Cell Conditioned Medium Activate the PI3K-Akt Pathway in Hypoxic Endothelial Cells to Inhibit Apoptosis, Increase Survival, and Stimulate Angiogenesis. Stem Cells 25, 2363-2370 (2007).
9. van Poll, D. et al. Mesenchymal Stem Cell-Derived Molecules Directly Modulate Hepatocellular Death and Regeneration In Vitro and In Vivo. Hepatology 47, 1634-1643 (2008).
10. Gao, Z. et al.Mesenchymal stromal cell-conditioned medium prevents radiationinduced small intestine injury in mice. Cytotherepy 14, 267-273 (2011).
11. Chang, Y. H. et al. Bone marrow transplantation rescues intestinal mucosa after whole body radiation via paracrine mechanisms. Radiother. Oncol. 105, 371-377 (2012).
12. Angoulvant, D. et al. Mesenchymal stem cell conditioned media attenuates in vitroand ex vivo myocardial reperfusion injury. J. Heart Lung Transplant 30, 95-102 (2011).
13. Yuen, W. W. et al. Mimicking nature by codelivery of stimulant and inhibitor to create temporally stable and spatially restricted angiogenic zones. Proc. Natl. Acad. Sci. USA. 107, 17933-17938 (2010).
14. Osugi, M. et al. Conditioned Media from Mesenchymal Stem Cells Enhanced Bone Regeneration in Rat Calvarial Bone Defects. Tissue Eng. Part A. 18, 1479-89 (2012).
15. Chang, C. P. et al. Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury. Clin. Sci. 124, 165-176 (2013).
16. Duijvestein, M. et al. Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 29, 1549-1558 (2011).
17. Herrmann, J. L. et al. Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. Shock. 33, 24-30 (2010).
18. Ren, G. et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2, 141-150 (2008).
19. Gunn, W. G. et al. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 24, 986-991 (2006).
20. Gonzalez-Rey, E. et al.Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 58, 929-939 (2009).
21. Tian, H. et al. A reserve stem cell population in small intestine renders Lgr5- positive cells dispensable. Nature 478, 255-259 (2011).
22. Yan, K. S. et al. The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. Proc. Natl. Acad. Sci. USA. 109, 466-471 (2012).
23. Chang, P. et al. Multi-therapeutic effects of human adipose-derived mesenchymal stem cells on radiation-induced intestinal injury. Cell Death Dis. 4, e685 (2013).
24. Hedger, M. P. & de Kretser, D. M. The activins and their binding protein, follistatin-Diagnostic and therapeutic targets in inflammatory disease and fibrosis. Cytokine Growth Factor Rev. 24, 285-295 (2013).
25. Ries, C. et al. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 109, 4055-4063 (2007).
26. Tondreau, T. et al. In vitro study of matrix metalloproteinase/tissue inhibitor of metalloproteinase production by mesenchymal stromal cells in response to inflammatory cytokines: the role of their migration in injured tissues. Cytotherapy 11, 559-569 (2009).
27. Qiu, W. et al. Growth factors protect intestinal stem cells from radiation-induced apoptosis by suppressing PUMA through the PI3K/AKT/p53 axis. Oncogene 29, 1622-1632 (2010).
28. Kanayama, M. et al. Hepatocyte growth factor promotes colonic epithelial regeneration via Akt signaling. Am J Physiol Gastrointest Liver Physiol. 293, G230-239 (2007).
29. Soleymaninejadian, E. et al. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol. 67, 1-8 (2012).
30. Terry, C. M. et al. TNF-a and IL-1a induce heme oxygenase-1 via protein kinase C, Ca21, and phospholipase A2 in endothelial cells. Am. J. Physiol. 276, H1493-H1501 (1999).
31. Liu, X. M. et al. Nitric Oxide Stimulates Heme Oxygenase-1 Gene Transcription via the Nrf2/ARE Complex to Promote Vascular Smooth Muscle Cell Survival. Cardiovasc. Res. 75, 381-389 (2007).
32. Tsubokawa, T. et al. Impact of anti-apoptotic and anti-oxidative effects of bone marrow mesenchymal stem cells with transient overexpression of heme oxygenase-1 on myocardial ischemia. Am. J. Physiol. Heart Circ. Physiol. 298, H1320-H1329 (2010).
33. Zarjou, A. et al. Paracrine effects of mesenchymal stem cells in cisplatin-induced renal injury require heme oxygenase-1. Am. J. Physiol. Renal. Physiol. 300, F254-F262 (2011).
34. Liang, O. D. et al. Mesenchymal Stromal Cells Expressing Heme Oxygenase-1 Reverse Pulmonary Hypertension. Stem Cells 29, 99-107 (2011).
35. Hou, C. et al. The effect of heme oxygenase-1 complexed with collagen on MSC performance in the treatment of diabetic ischemic ulcer. Biomaterials 34, 112-120 (2013).
36. Hang, C. H. et al. Expressions of Intestinal NF-kB, TNF-a, and IL-6 Following Traumatic Brain Injury in Rats. J. Surg. Res. 123, 188-193 (2005).
37. Hare, J. M. Translational development of mesenchymal stem cell therapy for cardiovascular diseases. Tex. Heart Inst. J. 36, 145-147 (2009).
38. Sémont, A. et al. Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis. Cell Death Differ. 17, 952-961 (2010).
39. Crisostomo, P. R. et al. Human mesenchymal stem cells stimulated by TNF-a, LPS, or hypoxia produce growth factors by an NFkB- but not JNK-dependent mechanism. Am. J. Physiol. Cell. Physiol. 294, C675-C682 (2008).
40. Nagaya, N. et al. Transplantation of Mesenchymal Stem Cells Improves Cardiac Function in a Rat Model of Dilated Cardiomyopathy. Circulation 112, 1128-1135 (2005).
41. Davis, M. E. et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc. Natl. Acad. Sci. USA. 103, 8155-8160 (2006).
42. Hunninghake, G. W. et al. Insulin-like Growth Factor-1 Levels Contribute to the Development of Bacterial Translocation in Sepsis. Am. J. Respir. Crit. Care Med. 182, 517-525 (2010).
43. Bortvedt, S. F. & Lund, P. K. Insulin-like growth factor 1: common mediator of multiple enterotrophic hormones and growth factors. Curr. Opin. Gastroenterol 28, 89-98 (2012).
44. Anguela, X. M. et al. Nonviral-Mediated Hepatic Expression of IGF-I Increases Treg Levels and Suppresses Autoimmune Diabetes in Mice. Diabetes 62, 551-560 (2013).
45. Zani, A. et al. Amniotic fluid stem cells improve survival and enhance repair of damaged intestine in necrotising enterocolitis via a COX-2 dependent mechanism. Gut. 63, 300-309 (2014).
46. Lorenzo-Zúñiga, V. et al. Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats. Gut. 55, 1306-1312 (2006).
47. Ko, I. K. et al. Targeting improves MSC treatment of inflammatory bowel disease. Mol. Ther. 18, 1365-1372 (2010).
48. Xu, C. et al. Nitric Oxide Donor Upregulation of Stromal Cell-Derived Factor-1/ Chemokine (CXC Motif) Receptor 4 Enhances Bone Marrow Stromal Cell Migration into Ischemic Brain After Stroke. Stem Cells 25, 2777-2785 (2007).
49. Hou, Y. et al. IL-8 enhances the angiogenic potential of human bone marrow mesenchymal stem cells by increasing vascular endothelial growth factor. Cell Biol Int. 38, 1050-1059 (2014).
50. Ulloa, L.&Tracey, K. J. The "cytokine profile": a code for sepsis. Trends Mol. Med. 11, 56-63 (2005).
51. Ko, T. C. et al. Transforming growth factor-beta inhibits rat intestinal cell growth by regulating cell cycle specific gene expression. Am. J. Surg. 167, 14-19 (1994).
52. Koutsopoulos, S. et al. Controlled release of functional proteins through designer self-assembling peptide nanofiber hydrogel scaffold. Proc. Natl. Acad. Sci. U. S. A. 106, 4623-4628 (2009).
53. Bakota, E. L. et al. Injectable multidomain peptide nanofiber hydrogel as a delivery agent for stem cell secretome. Biomacromolecules 12, 1651-1657 (2011).
54. Wang, Y. et al. Peptide nanofibers preconditioned with stem cell secretome are renoprotective. J. Am. Soc. Nephrol. 22, 704-717 (2011).
55. Bhang, S. H. et al. Efficacious and Clinically Relevant Conditioned Medium of Human Adipose-derived Stem Cells for Therapeutic Angiogenesis. Mol. Ther. 22, 862-872 (2014).